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 Synopsis 
Comparison of breast cancer sentinel lymph node processing protocols. Type and 
extent of intra- and postoperative pathological work-up respectively affects the 
accuracy of sentinel lymph node biopsies in terms of pN-status and detection of 
isolated tumor cells. 
 
1 
ABSTRACT 
Background: Recommendations for intra- and postoperative breast sentinel lymph 
node (SLN) processing differ widely. Micrometastases and isolated tumor cells (ITC) 
have recently been proposed as prognostically and therapeutically relevant. We 
compared three SLN protocols with regards to intra- and postoperative diagnosis.  
Methods: SLN in cohort I (270 patients) were intraoperatively assessed by 
stereomicroscopy. Intraoperative frozen section (IFS) was used only in 
stereomicroscopically suspicious SLN. In cohort II (197 patients), all SLN were 
examined with only one IFS. Final SLN work-up in cohort I and II consisted of 
complete step-sectioning with immunohistochemistry. In cohort III (268 patients) two 
or more IFS were performed followed by three step sections and 
immunohistochemistry.  
Results: pN1 stages were significantly higher in cohort I and II (33.3% and 34.0% 
resp.) than in cohort III (24.6%). Intraoperative false negativity for the detection of 
metastases (pN1) ranged from 54.4% (cohort I) and 35.8% (cohort II) to 21.2% 
(cohort III). In contrast, ITC were detected significantly more frequently in cohort I 
(9.3%) and cohort II (14.7%) than in cohort III (1.9%).  
Conclusions: Higher rates of SLN metastases and ITC in cohort I/II compared to 
cohort III suggest that IFS may result in tissue loss thus increasing the risk of missing 
metastases. Sparse IFS but complete postoperative SLN work-up with step-
sectioning and immunohistochemistry provides more accurate information regarding 
minimal disease in SLN, but often results in delayed axillary lymph node dissection. 
This is important for preoperative patient information and recommendations in SLN 
processing protocols.  
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INTRODUCTION 
The axillary nodal status is one of the most important prognostic factors in breast 
cancer [1, 2]. Intraoperative sentinel lymph node (SLN) biopsy is a good predictor of 
the axillary nodal status and is now a standard method in the assessment of patients 
with early breast cancer [3-6]. Despite the general acceptance of the SLN model, 
protocols for intra- and postoperative processing of SLN differ widely [7-11]. 
Intraoperative evaluation ranges from only gross examination, imprint cytology, one 
single intraoperative frozen section (IFS) to complete intraoperative step-sectioning 
with steps as small as 50μm including intraoperative immunohistochemistry and 
other molecular-based methods [12-15]. Postoperative evaluation includes 
hematoxylin and eosin (H&E) step sections, serial sectioning with or without auxiliary 
immunohistochemical stainings [12]. The accuracy of IFS and the rate of false 
negative intraoperative results depend on the intraoperative work-up of the SLN and 
the size of the metastasis. Some studies have demonstrated a good accuracy of IFS 
for macro-metastases, but not for small metastases or isolated tumor cells [3, 6]. 
Isolated tumor cells (staged as pN0(i+), with deposits ≤0.2 mm) and micrometastases 
(staged as pN1mi, with deposits >0.2 to ≤2.0 mm) have been assigned separate 
categories in the TNM staging [16]. The cutoff value of 0.2 mm was chosen 
arbitrarily. Recently, it has been suggested that patients with ITC or micrometastases 
have reduced disease-free survival and may profit from adjuvant therapy [1, 2].  
Due to the relevance of minimal metastatic disease in axillary lymph nodes, the 
intraoperative and postoperative examination of SLNs is of increasing importance. It 
is not surprising that increasing the precision the postoperative SLN work-up (e.g. 
with extensive use of cytokeratin step sections), will result in more intraoperative 
false negative cases, where the tumor was missed on a single or few H&E sections. 
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The complete intraoperative processing of the SLN with alternating H&E and 
cytokeratin step sections at 50µm intervals was proposed by Viale et al. [13]. The 
Swiss Section of Gynecological Pathologists has recommended an approach of one 
single IFS followed by complete postoperative step-sectioning using 200 µm 
intervals. Varga et al. have recently proposed the use of a stereomicroscope for the 
intraoperative assessment of SLN and preselection for IFS [9]. Stereomicroscopy 
consists of the examination of native unstained tissue samples with a magnification 
factor between 6 and 40, avoiding potential tissue loss associated with IFS of SLN 
[9]. 
In this study, we compared three large cohorts of patients with axillary SLN biopsies. 
In one cohort the primary stereomicroscopic approach with or without IFS was used, 
the second cohort was diagnosed using the conventional approach of one single IFS 
and diagnosis for the third cohort allowed two or more step sections for the IFS. The 
postoperative work-up varied from three step-sections to complete step-sectioning.  
4 
METHODS 
Study cohorts and protocols  
Cohort I (stereomicroscopy with one facultative intraoperative frozen section) 
This cohort included 270 consecutive breast cancer patients (651 SLN), diagnosed at 
the Institute of Surgical Pathology, University Hospital Zurich from August 2007 until 
end of July 2008. Sentinel lymph nodes were detected with standard radioactive 
tracers, partially in combination with blue dye [6]. SLN from these patients were 
processed as follows (Table 1): Axillary SLN were longitudinally bisected (or 
sectioned in 2 mm slices in SLN larger than 5 mm) and primarily assessed with a 
stereomicroscope. If the cut surface of the lymph node was clearly involved by the 
tumor or highly suspicious for malignancy, one single frozen section of the lymph 
node was performed [9]. In all other cases, lymph nodes were submitted to paraffin 
embedding and complete histological sectioning: paraffin blocks were completely 
step sectioned (200 µm steps) with one hematoxylin-eosin (H&E) staining and one 
unstained slide at each step. No residual lymph node structures remained in the 
paraffin block. If no tumor was found on the H&E slides, all unstained slides were 
immunostained with pan-cytokeratin (Lu5, 1:250, Roche, Basel, Switzerland) using 
standard immunohistochemical protocols and Ventana Benchmark autostainer 
platforms (Ventana, Tucson, AZ, USA). Lymph nodes that were found positive (pN1) 
at IFS were fixated with formalin and embedded in paraffin and stained with one 
H&E. Additional cytokeratin immunostaining was applied if considered necessary.  
The mean number of lymph nodes per case was 2.4 (median 2; range 1-8). The 
mean size of the lymph node was 11.2 mm (median 10 mm). The median size of the 
invasive carcinomas in this cohort was 16 mm (mean 19.9 mm). The median size of 
lymph node metastases was 3.6 mm (mean 5.1 mm; range 0.2-25 mm). 
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Cohort II (only one compulsory intraoperative frozen section) 
This cohort included 197 consecutive breast cancer patients (476 SLN), diagnosed at 
the Institute of Surgical Pathology, University Hospital Zurich from August 2004 until 
end of July 2005. SLN from these patients were processed as follows (Table 1): All 
SNL were bisected (or sectioned deeper in 2 mm slices if large enough) and one 
intra-operative frozen section stained with H&E was performed on each SLN 
irrespectively of the gross appearance of the SLN. The residual SLN tissue was 
submitted to paraffin embedding and complete histological sectioning as described at 
cohort I.  
The mean number of lymph nodes per case was 2.4 (median 2; range 1-8). The 
mean size of the lymph node was 10.2 mm (median 10 mm). The median size of the 
invasive carcinomas in this cohort was 16 mm (mean 17.7). The median size of these 
metastases was 3 mm (mean 4.8 mm; range 0.2-20 mm). 
 
Cohort III (at least two or more intraoperative frozen sections) 
This group included 268 consecutive breast cancer patients (472 SLN), diagnosed at 
the Institute of Pathology, Charité University Hospital Berlin from August 2007 until 
end of July 2008. SLN from these patients were examined as follows (Table 1): All 
SNL were bisected (or sectioned in 2 mm slices in larger SLN). At least two 
(optionally more) IFS with H&E were performed on each SLN regardless of the gross 
appearance of the SLN. If the IFS was positive, the residual SLN tissue was 
embedded in paraffin and only one H&E stain was made. If the IFS was negative, 
residual SLN tissue was submitted to paraffin embedding and three H&E step-
sections (150 µm steps) were performed, accompanied by one pan-cytokeratin 
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immunostaining (MNF116, 1:1000, Dako, Glostrup, Denmark) using Benchmark XT 
autostainers (Ventana). 
The mean number of lymph nodes per case was 1.8 (median 1; range 1-7). The 
mean size of the lymph node was 11.4 mm (median 10 mm). The median size of the 
invasive carcinomas in this cohort was 18 mm (mean 20.3 mm). The median size of 
metastases was 5 mm (mean 6.9 mm, range 0.2-35 mm).  
 
Assessment of potential tissue loss  
To evaluate the potential effects of tissue loss on the number and size of lymph node 
metastasis we analyzed two subgroups of the cohorts I and II. The first subgroup 
comprised all cases from cohort I which were inconspicuous in stereomicroscopy and 
thus left uncut in the IFS. The second group included cases that had one single IFS 
from cohort I and II but were considered negative in the IFS. 
 
Statistical analyses 
We analyzed the sensitivity, specificity, positive and negative predictive values and 
accuracy of each protocol. Further, we assessed differences between the cohorts 
and for cases with and without IFS concerning nodal metastases and presence of 
ITC. Furthermore all three cohorts were compared to in terms of clinico-pathological 
data to ensure comparability (Mann-Whitney-U). Statistical analyses were performed 
using Microsoft Excel 2007 and SPSS Version 18.0. P-values < 0.05 were 
considered significant. 
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RESULTS 
Comparability of the cohorts 
There was no statistically significant difference concerning the basic tumor 
parameters tumor type, pT-status and histological grading between cohorts I and II 
(Table 2). A high pT-status was significantly more frequent in cohort III compared to 
cohort II (p=0.031). The histological grade was higher in cohort I compared to cohort 
III (p=0.019). There was no statistical difference between the combined cohorts I and 
II and cohort III  
 
Definitive Diagnosis - More frequent pN1 stages and ITC in cohort I and II 
Cohorts I and II comprised 270 and 197 breast cancer patients with 90 and 67 lymph 
node metastases respectively (Table 2). The frequency of pN1 stages did not differ 
between these two cohorts (33.3% vs. 34.0%). Isolated tumor cells (ITC) were 
slightly more frequent in cohort II (14.7%) than in cohort I (9.3%). Cohorts I and II (no 
or one IFS) were compared to cohort III (n=268) with two or more IFS. The frequency 
of patients with positive SLN (pN1) was significantly lower in cohort III (24.6%) if 
compared to cohort I (33.3%; p=0.016), cohort II (34%; p=0.027) or cohort I and II 
combined (p=0.008). ITC were detected in five patients (1.9%) of cohort III. This was 
significantly less than in cohorts I (9.3%) and II (14.7%), either taken solitary or in a 
combined analysis (each p<0.001).  
 
Intraoperative Diagnosis – False negativity is related to sparse IFS 
The sensitivity of the IFS for the detection of metastatic deposits was higher in cohort 
II (64.2%) compared to cohort I (45.6%, Table 3). Likewise the negative predictive 
value (NPV) (84.3% versus 78.6%) and the accuracy (87.3% versus 81.9%) were 
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higher in cohort II. Specificity and positive predictive values (PPV) were between 
97.7% and 100% in both cohorts. In cohort II, one IFS was false positive due to a 
misinterpretation of large cells with mitotic figures as micro-metastasis. Histological 
tumor type was not a relevant factor in any of the three protocols for intra- or 
postoperative detection of metastasis. Representative cases of corresponding 
stereomicroscopic and histological results are displayed in Figure 1. Theses cases 
also demonstrate typical difficulties encountered with stereomicroscopic 
assessments. 
 
With 78.8%, the sensitivity of IFS in cohort III was clearly above that of cohort I and 
II. The NPV (93.5%) and accuracy (94.8%) in cohort III were also distinctly above 
that of either of the other cohorts. Specificity and PPV were 100%. One SLN was 
intraoperatively false positive due to the misinterpretation of an adenosis nodule.  
 
Within cohort I, lymph node metastases were more frequent in those lymph nodes 
without an IFS (cohort I) compared to SLN with one IFS (cohort I and II; 13.9% vs. 
7.6%, p=0.002; Table 4), whereas ITC were only slightly more often detected in the 
group with IFS (5.3% vs. 8%).  
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DISCUSSION 
The three different protocols for axillary SLN processing analyzed in this study 
revealed significantly higher rates of SLN metastases and ITC in protocols with few 
IFS combined with complete postoperative work-up. In contrast, few IFS increased 
the rate of intra-operative false negative SLN diagnosis with the potential 
consequence of delayed axillary lymph node dissection. The protocol of SLN 
processing is therefore relevant in the debate of short- or long-term outcome data of 
clinical trials [2, 17].  
 
Very recently, de Boer et al. presented a large study demonstrating that patients with 
ITC had decreased disease free survival and that chemotherapy improved survival in 
these patients [2]. This study renewed interest in the implications of the presence of 
ITC [18-20]. Our study demonstrates now how significantly the results of the SLN 
biopsy are influenced by the pathological work-up protocol applied. We found a more 
than fourfold difference between cohort III and the other two cohorts in the detection 
of ITC. Since this study was observational in design this certainly implicates potential 
biases of the results. However, our analyses of the most important tumor parameters 
(pT status, grading, tumor type) did not reveal relevant differences between the three 
cohorts that could explain for such variances. Therefore, the demonstrated 
differences in the amount of ITC are almost certainly due to the lesser extent of 
immunohistological work-up in cohort III. This implies that the validity of results of 
clinical trials studying the association of ITC and outcome of breast cancer should 
take into account the extent of the SLN work up in pathology. The biological 
relevance of ITC has not been clearly determined yet [21-24]. Rutgers suggested 
only using SLN processing protocols that identify lymph node metastases of known 
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clinical relevance [25]. Different SLN protocols in various breast centers, sufficient 
follow-up time and adequate clinical screening for metastases are potential 
limitations and prerequisites of clinical studies to evaluate the relationship between 
ITC or micrometastases with clinical outcome [26].  
 
Our results further show that two or more intraoperative step-sections resulted in a 
better intraoperative sensitivity to detect lymph node metastases compared to a 
single IFS-only model, which can be regarded as a clear argument to use two or 
more intraoperative step-sections. Higher intraoperative sensitivity and accuracy are 
helpful to avoid delayed axillary lymph node dissection, thereby lowering iatrogenic 
morbidity. Importantly, our findings suggest that a higher intraoperative detection rate 
for metastases with more than one IFS was also accompanied by a significantly 
lower rate of metastases in the final diagnosis. This supports the hypothesis that 
tissue loss occurs during the procedure of IFS [9], which might have been one 
reason for recommendations in the United Kingdom of not performing IFS [12]. To 
avoid tissue loss was also the basic concept for using stereomicroscopic preselection 
of SLN for IFS as described by Varga et al. [9]. 
 
Concerning stereomicroscopy, our data suggest that the 
macroscopic/stereomicroscopic preselection of SLN can not be recommended, 
because this approach does not lead to significantly higher rates of postoperatively 
detected metastases in comparison to a protocol with one single IFS. Instead 
stereomicroscopic preselection led to a very high rate of intraoperative false 
negativity (54.4%). As seen in Figure 1 some metastases are invisible to the naked 
eye or stereomicroscopy. Theoretically, specimens with intense blue dye staining 
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could also make it harder for the pathologist to interpret the stereomicroscopic 
results. However, the latter situation constituted no major problem in our experience. 
Since the cohorts without or with one IFS showed similar rates of pN1 stages (33.3% 
vs. 34%) and ITC (14.7% vs. 9.3%), this supports a recommendation to do at least 
one IFS intraoperatively. Nonetheless it has to be noted that the intraoperative false 
negativity rate with a single IFS was still high (35.8%) compared to the use of two 
and more IFS (21.2%). This phenomenon can be explained by the location of the 
metastatic deposits in deeper planes of the SLN. Since a single IFS only detects 
metastases located on the cutting plane of the lymph node we analyzed how many of 
the metastases were found on the cutting plane and how many on deeper step 
sections only. From 157 patients with SLN metastases in cohorts I and II, 48 (30.6%) 
were not detectable on the first step-section. From the 54 patients where ITC were 
the only finding, for 28 (51.9%) cases the ITC were only detectable on deeper step-
sections. Figure 2 illustrates the problem of metastases in deeper cutting planes. 
None of the protocols showed any tumor type specific advantages or disadvantages. 
 
Economical questions have to be also taken into account for the recommendation of 
SLN processing protocol. Viale et al. propose the complete intraoperative processing 
of the SLN with alternating H&E and cytokeratin step sections at 50µm intervals [13]. 
Considering that the number of SLN submitted might easily exceed one or two, the 
costs and time of such a complete intraoperative work-up as well as the obligation to 
meet also the intraoperative demands of other surgical specialities, such a protocol is 
difficult to implement in a cost- and time-efficient way in most pathology laboratories. 
Although we did not specifically compare the exact IFS times of the protocols, in this 
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context it should be noted that none of the three evaluated protocols exceeded a 30 
minute time limit for IFS.  
 
In conclusion, our presented data support a strong dependence between the use of 
IFS and extent of step-sectioning with intraoperative sensitivity/accuracy and 
potential tissue loss. Some surgeons believe that the possibility for an axillary lymph 
node dissection during initial surgery outweighs the risk of missed metastases [6, 27]. 
In our opinion, this is a point that should be decided under consideration of the 
patients physical condition and preferences. The highest rate of metastasis detection 
is reached by omission of IFS or one single IFS followed by a thorough and 
immunohistochemically supported work-up of the SLN. Stereomicroscopic-based 
assessment could not be recommended due to high intraoperative false negativity. If 
the presence of ITC should become decisive for treatment selection, the current high 
variability of protocols in the detection of ITC has to be seriously reconsidered.  
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TABLES 
TABLE 1 Three different protocols for the intra- and postoperative assessment of 
sentinel lymph nodes (SLN) 
 
Cohort I 
 
Cohort II 
 
Cohort III 
 
longitudinal bisection of the 
SLN 
longitudinal bisection of the 
SLN 
longitudinal bisection of the 
SLN 
 
stereomicroscopic examination 
 
One IFS 
 
≥ two IFS  
 
 
suspicious for 
cancer 
 
not suspicious 
 
positive 
 
negative 
 
positive 
 
negative 
 
 
one IFS 
 
if positive 
 
one H&E 
staining 
 
if negative 
see right 
column 
no IFS 
 
 
 
complete 
work-up of 
SLN in H&E 
step sections 
(200 µm) and 
unstained 
slides for 
cytokeratin 
 
 
 
 
 
one H&E 
staining 
 
 
 
 
complete 
work-up of 
SLN in H&E 
step sections 
(200 µm) and 
unstained 
slides for 
cytokeratin 
 
 
 
 
 
one H&E 
staining 
 
 
 
 
work-up of 
SLN in three  
H&E step 
sections (150 
µm) and one 
cytokeratin 
staining 
IFS: intraoperative frozen section, H&E: haematoxylin & eosin.
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TABLE 2 Tumor and lymph node characteristics of cohort I, II and III  
Parameter Cohort I 
(%) 
Cohort II 
(%) 
Cohort III 
(%) 
Number of cases 270 (100%) 197 (100%) 268 (100%) 
Tumor histology 
Invasive Ductal Carcinoma 
Invasive Lobular Carcinoma 
Other cancer types 
 
216 (80.0%) 
42 (15.6%) 
12 (4.4%) 
 
162 (82.2%) 
29 (14.7%) 
6 (3.0%) 
 
209 (78.0%) 
41 (15.3%) 
18 (6.7%) 
pT-status* 
pT1 
pT2 
pT3 
multifocal (m)#
 
170 (63.0%) 
85 (31.5%) 
14 (5.2%) 
29 (10.7%) 
 
138 (70.1%) 
53 (26.9%) 
5 (2.5%) 
19 (9.7%) 
 
163 (60.8%) 
93 (34.7%) 
11 (4.1%) 
35 (13.1%) 
Histological tumor grading* 
G1 
G2 
G3 
 
48 (17.8%) 
127 (47.0%) 
88 (32.6%) 
 
48 (24.4%) 
93 (47.2%) 
53 (26.9%) 
 
51 (19.0) 
157 (58.6) 
58 (21.6) 
Patient nodal status 
pN0/pN0 i+ 
pN1 
 
155 (57.4%)/25 (9.3%) 
90 (33.3%) 
 
101 (51.3%)/29 (14.7%) 
67 (34.0%) 
 
197 (73.5%)/5 (1.9%) 
66 (24.6%) 
*No pT status was available for one case in each cohort and no grade was given for 
seven cases in cohort I, three cases in cohort II and two cases in cohort III.  
#Multifocal tumors were extracted from other pT stages for comparative reasons and 
were otherwise included with the pT stage that matched with the largest tumor 
nodule. 
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TABLE 3 Comparison of intraoperative frozen section diagnosis with final 
diagnosis (after formalin fixation and paraffin embedding). Section 1 displays the 
patient result irrespective of the number of lymph nodes submitted to frozen 
section. Section 2 depicts the results for single lymph nodes, since often more 
than one sentinel lymph node was submitted.  
Cohort I                                                                                                           section 1  
Final Result Intraoperative Result 
positive negative 
Sum 
positive 41 (45.6%) 0 (0%) 41 
negative 49 (54.4%) 180 (100%) 229 
Sum 90 (100%) 180 (100%) 270 
Cohort I                                                                                                           section 2 
Final Result Intraoperative Result 
positive negative 
Sum 
positive 48 (37.2%) 0 (0%) 48 
negative 81 (62.8%) 522 (100%) 603 
Sum 129 (100%) 522 (100%) 651 
Cohort II                                                                                                           section 1 
Final Result Intraoperative Result 
positive negative 
Sum 
positive 43 (64.2%) 1 (0.8%) 44 
negative 24 (35.8%) 129 (99.2%) 153 
Sum 67 (100%) 130 (100%) 197 
Cohort II                                                                                                           section 2 
Final Result Intraoperative Result 
positive negative 
Sum 
positive 62 (68.9%) 1 (0.3%) 63 
negative 28 (31.1%) 385 (99.7%) 413 
Sum 90 (100%) 386 (100%) 476 
Cohort III                                                                                                           section 1 
Final Result Intraoperative Result 
positive negative 
Sum 
positive 52 (78.8%) 0 (0%) 52 
negative 14 (21.2%) 202 (100%) 216 
Sum 66 (100%) 202 (100%) 268 
Cohort III                                                                                                           section 2 
Final Result Intraoperative Result 
positive negative 
Sum 
Positive 75 (83.3%) 1 (0.3%) 76 
Negative 15 (16.7%) 381 (99.7%) 396 
Sum 90 (100%) 382 (100%) 472 
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TABLE 4 Comparison of lymph node status in sentinel lymph nodes without 
intraoperative frozen section (cohort 1) and with intraoperative frozen section (cohort 
1 and 2 combined). 
Parameter One IFS performed 
(%) 
No IFS performed 
(%) 
p-value 
Lymph node status 
pN0/pN0 i+ 
pN1 
 
420 (84.3%)/40 (8.0%) 
38 (7.6%) 
 
412 (80.8%)/27 (5.3%) 
71 (13.9%) 
0.002 
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FIGURE LEGENDS 
FIGURE 1 Stereomicroscopic and matching histological results (magnification 6x, 
inlet 200x) 
A SLN with macro-metastasis visible in stereomicroscopy (A1) and in the matching 
H&E staining (A2). B Stereomicroscopically suspect SLN (B1) with fibrosis and 
lipomatosis in the histological section (B2). C Stereomicroscopically unsuspicious 
SLN (C1) with macro-metastasis on the first H&E section (C2). 
 
FIGURE 2 Two step-sectioned SLN with different tumor localizations 
In contrast to the macro-metastasis (arrowhead) in SLN A, maximum in the cutting 
plane, the one in SLN B would probably be missed by stereoscopic or single IFS 
assessment. Detecting micro-metastases or ITC (arrows) is a challenge in the H&E 
staining regardless of the localization. 
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